Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure.
The effects of oral milrinone treatment in cardiomyopathic hamsters with severe congestive heart failure (CHF) were evaluated. Strict criteria based on increase in body weight were established to define day no 1 of treatment. Survival rate of non-treated hamsters (group 1) ranged between 9 and 16 d, mean 12.9 (SEM 0.8) d, after entering the study. Hamsters treated with milrinone in drinking water (group 2a: 0.3 mg.ml-1, or group 2b: 0.6 mg.ml-1) survived between 6 and 36 d, mean 15.0(2.1) d, NS, for group 2a, and between 6 and 47 d, mean 19.6(4.0) d, NS, for group 2b. There was a significant difference between the number of hamsters that survived longer than 16 d between untreated hamsters (group 1, n = 0/12) and hamsters treated with milrinone (groups 2a, b, n = 7/24). There was no significant correlation between survival duration and milrinone daily dose nor between survival and milrinone plasma concentration at death. Milrinone treatment also significantly decreased pulmonary congestion as measured by the number of pigment containing macrophages per alveolus. No other pathological findings were modified by milrinone. It was concluded that, in addition to exerting a beneficial effect on pulmonary congestion, milrinone improved survival in some CHF hamsters. However, more studies are needed to evaluate the possibility of an arrythmogenic potential that might explain why some treated hamsters died earlier than non-treated hamsters.
Desjardins
S
S
Health Protection Branch, Bureau of Drug Research, Ottawa, Canada.
Mueller
R W
RW
Hubert
R S
RS
Cauchy
M J
MJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002118:Calcium / Q000032:analysis; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000235:genetics; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008274:Magnesium / Q000032:analysis; D008297:Male; D008647:Mesocricetus / Q000235:genetics; D020105:Milrinone; D011654:Pulmonary Edema / Q000209:etiology / Q000517:prevention & control; D011728:Pyridones / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D011728:Pyridones; D008274:Magnesium; D020105:Milrinone; D002118:Calcium